Veracyte, Inc.
VCYT
Kedudukan dalam Saham
#4437
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Harga Saham
$43.73
Modal Pasaran
$3.52B
Perubahan (1 hari)
1.40%
Perubahan (1 tahun)
22.03%
Negara
US
Perdagangan Veracyte, Inc. (VCYT)
Kategori
Healthcare
EPS untuk Veracyte, Inc. (VCYT)
EPS setakat June 2026 TTM: $1.44
Menurut laporan kewangan terkini dan harga saham Veracyte, Inc., EPS semasa syarikat (TTM) adalah $1.44. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-1.02 peningkatan berbanding EPS tahun 2022 iaitu $-0.51.
Sejarah EPS untuk Veracyte, Inc. dari 2011 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $1.44 | 350.00% |
| 2024 | $0.32 | -131.37% |
| 2023 | $-1.02 | 100.00% |
| 2022 | $-0.51 | -54.05% |
| 2021 | $-1.11 | 68.18% |
| 2020 | $-0.66 | 144.44% |
| 2019 | $-0.27 | -56.45% |
| 2018 | $-0.62 | -31.87% |
| 2017 | $-0.91 | -16.51% |
| 2016 | $-1.09 | -16.15% |
| 2015 | $-1.30 | -4.41% |
| 2014 | $-1.36 | -77.89% |
| 2013 | $-6.15 | 369.47% |
| 2012 | $-1.31 | 28.43% |
| 2011 | $-1.02 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $18.62 | 1,193.06% |
US
|
|
| $5.65 | 292.36% |
US
|
|
| $-1.36 | -194.44% |
US
|
|
| - | - |
CN
|
|
| $5.09 | 253.47% |
US
|
